Vical Shares Surge as Seeking Alpha Highlights Strong Results on Allovectin-7 Trial

Shares of Vical Inc.

have charged into positive territory Tuesday afternoon following a bullish Seeking Alpha article "

." The stock is now up 5.5 percent to $3.63; shares had traded between the $3.40 level and the $3.45 level throughout much of Tuesday's session ahead of the positive article. The article gives a thorough fundamental analysis of Vical, offering a breakdown of the "solid tumor addressable market for Allovectin-7 at over $25 billion a year," and the company's cash and debt levels. Volume in the name spiked sharply as the article began making the rounds. More than 1.7 million shares of Vical have now traded Tuesday, compared to the stock's average daily volume around 800,000 shares.